References
- Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans – immunotherapy of patients with advancedmelanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:1–9. DOI:10.1056/NEJM199008303230904
- Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 official journal of the European Union; 2007 Dec 10.
- Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 official journal of the European Union; 2007 Dec 10. [cited 2016 Sept 28]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf
- FDA. Guidance for industry, gene therapy clinical trials – observing subjects for delayed adverse events; 2006 Nov. [cited 2016 Sept 28]. Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072957.htm
- Kumar S, Markusic D, Biswas M, et al. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther-Methods Clin Dev. 2016;3:16034. DOI:10.1038/mtm.2016.34
- Boye SE, Boye SL, Lewin AS, et al. A comprehensive review of retinal gene therapy. Mol Ther. 2013;21:509–519. DOI:10.1038/mt.2012.280
- Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013;120:1283–1291. DOI:10.1016/j.ophtha.2012.11.048
- Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360:447–458. DOI:10.1056/NEJMoa0805817
- European Medicines Agency, Glybera EPAR. [cited 2016 Sept 28]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/human_med_001480.jsp&mid=WC0b01ac058001d124
- European Medicines Agency, Imlygic EPAR. [cited 2016 Sept 28]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002771/human_med_001941.jsp&mid=WC0b01ac058001d124
- European Medicines Agency, Strimvelis EPAR. [cited 2016 Sept 28]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003854/human_med_001985.jsp&mid=WC0b01ac058001d124
- FDA site, biologics, vaccines & blood approved products list. [cited 2016 Sept 28]. Available from: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/
- Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 – an update. J Gene Med. 2013;15:65–77. DOI:10.1002/jgm.v15.2
- The Journal of Gene Medicine Clinical Trial site. Available from: http://www.abedia.com/wiley/
- European Society of Gene Therapy. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). J Gene Med. 2003;5:82–84. DOI:10.1002/(ISSN)1521-2254
- Gansbacher B. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European society of gene therapy (ESGT). J Gene Med. 2003;5:261–262. DOI:10.1002/(ISSN)1521-2254
- Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244–2245. DOI:10.1126/science.286.5448.2244
- Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148–158. DOI:10.1016/j.ymgme.2003.08.016
- Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132–3142. DOI:10.1172/JCI35700
- Ylä‐Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20:1831–1832. DOI:10.1038/mt.2012.194
- Available from: http://www.uniqure.com/products/glybera/
- Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to Article 14 (8) of regulation (EC) NO 726/2004, EMA. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004883.pdf
- Wilkinson B, Bennett C. Will reimbursement prove to be the biggest barrier as three gene therapies gain regulatory approval? 2016 Jul. Report reference: DMKC0162772.
- Keyhani S, Wang S, Hebert P, et al. US pharmaceutical innovation in an international context. Am J Public Health. 2010;100(6):1075–1080. DOI:10.2105/AJPH.2009.178491
- Cockburn IM. The changing structure of the pharmaceutical industry. Health Aff. 2004 Jan;23(1):10–22. DOI:10.1377/hlthaff.23.1.10
- McGovern V. Getting grants. Virulence. 2012;3(1):1–11. DOI:10.4161/viru.3.1.18844
- NON-NIH Grants, NYU silver school of social work. [cited 2016 Sept 29]. Available from: http://socialwork.nyu.edu/faculty-and-staff/office-for-research/grants-pre-award/non-nih-grants.html
- Rasmussen E, Wright M. How can universities facilitate academic spin-offs? An entrepreneurial competency perspective. J Technol Transf. 2015;40:782–799. DOI:10.1007/s10961-014-9386-3
- Tax incentives for research and development: trends and issues. OECD. [cited 2016 Sept 29]. Available from: http://www.oecd.org/sti/inno/2498389.pdf
- Guidance: Corporation Tax: Research and Development tax relief, HM Revenue & Customs. 2016. Available from: https://www.gov.uk/guidance/corporation-tax-research-and-development-rd-relief
- Pharmaceutical Research and Manufacturers of America. Nearly 800 new medicines in development to help in the fight against cancer; 2014 Oct 6 [cited 2015 Mar 12]. Available from: www.phrma.org/research/cancer
- Buffery D. The 2015 oncology drug pipeline: innovation drives the race to cure cancer. Am Health Drug Benefits. 2015;8(4):216–222.
- Boudes P. Gene therapy as a new treatment option for inherited monogenic diseases. Eur J Int Med. 2014;25:31–36. DOI:10.1016/j.ejim.2013.09.009
- Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011;9:275–279. DOI:10.2165/11590170-000000000-00000
- European Parliament: Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16. December on orphan medicinal products, Official journal of the European communities, L 18/5; 1999 [cited 2000 Jan 22]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF
- For France, other tax exemption authorised by EU in 2002 Jun (state aid authorised by the EU until 2013 Dec 31). [cited 2016 Sept 29]. Available from: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2002:284:0002:0002:EN:PDF
- Hanna E, Remuzat C, Auquier P, et al. Advanced therapy medicinal products: current and future perspectives. J Mark Access Health Policy. 2016;4:31036. DOI:10.3402/jmahp.v4.31036
- Gruber K. Europe gives gene therapy the green light. Lancet. 2012;380:e10. DOI:10.1016/S0140-6736(12)61992-8
- Nayerossadat N, Maedeh T, Ali PA. Viral and non-viral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27. DOI:10.4103/2277-9175.98152
- Hirai H, Satoh E, Osawa M, et al. Use of EBV-based vector/ HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem Biophys Res Commun. 1997;241:112–118. DOI:10.1006/bbrc.1997.7776
- Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295–304. DOI:10.1038/gt.2009.148
- Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012;20(2):443–455. DOI:10.1038/mt.2011.237
- Pelkmans J, Renda A. Does EU regulation hinder or stimulate innovation? 2014 Nov. (CEPS Special Report No. 96). [cited 2016 Oct 2]. Available from: https://www.ceps.eu/system/files/No%2096%20EU%20Legislation%20and%20Innovation.pdf
- Eichler H. The regulatory framework as a facilitating environment for innovation. Brussels: EC Scientific Panel for Health; 2016.
- Glybera, Brief Summary of the transparency committee opinion. HAS; 2015 Nov. [cited 2016 Oct 2]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-05/glybera_summary_ct14224.pdf
- Zusatznutzen von Glybera® (Wirkstoff: Alipogentiparvovec) nicht quantifizierbar. G-BA; 2015 May. [cited 2016 Oct 3]. Available from: https://www.g-ba.de/institution/presse/pressemitteilungen/578/
- Bruger L, Hirschler B, Exclusive: First gene therapy drug sets million-euro price record. 2014. [cited 2016 Oct 3]. Available from: http://www.reuters.com/article/us-health-genetherapy-price-idUSKCN0JA1TP20141126
- Hanna E, Zhou J, Cheng X, et al. Advanced therapy medicinal products for Alzheimer’s disease will shrink the national health service budget. Paper Presented at: ISPOR 19th European Meeting; 2016; Oct 31–Nov 2; Vienna, Austria. DOI:10.1016/j.jval.2016.09.1024
- Hanna E, Ma F, Cheng X, et al. Future innovative therapies for Parkinson’s disease may question sustainability of our health care system. Paper Presented at: ISPOR 19th European Meeting; 2016 Oct 31–Nov 2; Vienna, Austria. DOI:10.1016/j.jval.2016.09.528
- Hanna E, Dorey J, Aballéa S, et al. Will stem cells for heart failure be the next Sofosbuvir issue? Paper Presented at: ISPOR 19th European Meeting; 2016 Oct 31–Nov 2; Vienna, Austria. DOI:10.1016/j.jval.2016.09.1781
- Edlin R, Hall P, Wallner K, et al. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? Value Health. 2014;17:438–444. DOI:10.1016/j.jval.2014.01.010
- Kleinke JD, McGee N. Breaking the bank: three financing models for addressing the drug innovation cost crisis. Am Health Drug Benefits. 2015 May;8(3):118–126. Review.
- Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries: review. Health Syst Transit. 2016;18(5). [cited 2016 Oct 10]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0019/322444/HiT-pharmaceutical-regulation-15-European-countries.pdf
- Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMINET; 2013. ( Final Report).
- Licking E, Garfield S. A road map to strategic drug pricing. Vivo Bus Med Rep. 2016;34(3):1–11.
- Kusel J, Spoors J. Recent trends in the pricing of high-cost pharmaceuticals. Br J Healthc Manage. 2016;22(5):267–277. DOI:10.12968/bjhc.2016.22.5.267